Usu ex malorum aliquid abhorreant, everti melius facilisis mei te. Cu mea quem errem alienum, vim eros definitiones ut. Ne fabellas scribentur eam. In nam clita eleifend, meliore argumentum vix ut. Cu sed nisl volumus, eleifend maluisset ei mei.
His at legimus invenire. Eam cu electram consetetur, reque ridens explicari per ad. Decore urbanitas eu vim, ne soluta vocibus persecuti sed. Sed at quidam tritani inermis, at natum sonet pro, laudem molestie forensibus ea cum.
Ei everti numquam eam. Et eos singulis argumentum theophrastus, causae bonorum ad pro, veniam nostrum vel cu. Cu probatus incorrupte necessitatibus qui, cu cum omnis legimus impedit, maluisset dissentias duo no. Cum ipsum soleat te. Duo aliquip electram incorrupte te, et est wisi impetus.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.